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Abstract
A growing body of evidence suggests a protective role of vitamin D on the risk of type 2 dia-
betes mellitus (T2DM). We investigated this relationship in a population sample from one
Australian state. The data of 3,393 Australian adults aged 18–75 years who participated in
the 2009–2010 Victorian Health Monitor survey was analyzed. Socio-demographic informa-
tion, biomedical variables, and dietary intakes were collected and fasting blood samples
were analyzed for 25, hydroxycholecalciferol (25OHD), HbA1c, fasting plasma glucose
(FPG), and lipid profiles. Logistic regression analyses were used to evaluate the association
between tertiles of serum 25OHD and categories of FPG (<5.6 mmol/L vs. 5.6–6.9 mmol/L),
and HbA1c (<5.7% vs. 5.7–6.4%). After adjusting for social, dietary, biomedical and meta-
bolic syndrome (MetS) components (waist circumference, HDL cholesterol, triglycerides,
and blood pressure), every 10 nmol/L increment in serum 25OHD significantly reduced the
adjusted odds ratio (AOR) of a higher FPG [AOR 0.91, (0.86, 0.97); p = 0.002] and a higher
HbA1c [AOR 0.94, (0.90, 0.98); p = 0.009]. Analysis by tertiles of 25OHD indicated that after
adjustment for socio-demographic and dietary variables, those with high 25OHD (65–204
nmol/L) had reduced odds of a higher FPG [AOR 0.60, (0.43, 0.83); p = 0.008] as well as
higher HbA1c [AOR 0.67, (0.53, 0.85); p = 0.005] compared to the lowest 25OHD (10–44
nmol/L) tertile. On final adjustment for other components of MetS, those in the highest tertile
of 25OHD had significantly reduced odds of higher FPG [AOR 0.61, (0.44, 0.84); p = 0.011]
and of higher HbA1c [AOR 0.74, (0.58, 0.93); p = 0.041] vs. low 25OHD tertile. Overall, the
data support a direct, protective effect of higher 25OHD on FPG and HbA1c; two criteria for
assessment of risk of T2DM.
Introduction
Vitamin D status, as judged from circulating concentrations of 25, hydroxycholecalciferol
(25OHD), is a worldwide concern. In many countries across all continents, approximately
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50% of those populations have an inadequate 25OHD status (<50 nmol/L) [1]. Countries like
India and China have some of the highest rates of vitamin D deficiency (<25 nmol/L) [1]. The
25OHD status of Australians is also surprisingly low for a country blessed with abundant sun-
shine. Current estimates indicate that ~31% of the population have inadequate 25OHD levels
[2], with a higher prevalence in older Australians [3]. The prevalence of type 2 diabetes melli-
tus (T2DM) has also risen tremendously in the last 10 years, with projections that countries
like India and China will have the highest numbers by 2030 at 79.4 and 42.3 million respec-
tively [4].
There is an ongoing interest in the extra-skeletal effects of vitamin D including its potential
to blunt the risk of developing T2DM. Positive outcomes would present a tangible public
health solution, if causality is accepted. Such a relationship was first suggested in 1967 by Mil-
ner and Hales, who found that insulin secretion in rabbits was dependent on calcium and mag-
nesium, which are tightly regulated by vitamin D [5]. Accumulating evidence has indicated
that higher 25OHD status may have several anti-diabetic effects, including improvement in
insulin sensitivity, stabilizing HbA1c levels [6], and improving beta cell function [7], whereas
low 25OHD status may increase risk of T2DM [8]. Thus, in the current environment of increas-
ing rates of T2DM [9], their close parallelism with insufficient levels of 25OHD deserves investi-
gation in population based studies. There are several lifestyle factors that modulate the risk of
T2DM, including dietary components and patterns [10, 11], physical activity, and smoking
[12]. The risk of developing T2DM over 20 years appears to increase with the accumulation of
metabolic syndrome (MetS) components. The risk of T2DM increased by: 11.9% in those with
zero Mets components, 31.2% in those with three MetS components and 40.8% in those with
four or five MetS components [13]. Though the presence of MetS components increases the
risk of T2DM, glucose is the most strongly correlated factor in predicting the development of
diabetes in the future [14]. In a study of more than 58,000 adults, as the number of components
increased, so did the incidence of diabetes [14]. However, some gaps may exist with one study
in Hispanic Americans finding that impaired glucose tolerance had a greater predictive power
than the individual MetS components [15]. Thus, the presence of MetS is another major risk
predictor of increased T2DM [16].
The aim of this study was to investigate the association of 25OHD, and the risk of T2DM.
We [17] as well as others [18–21], have shown that higher 25OHD status significantly reduced
the risk of MetS and its components. Hence it was essential to adjust for several lifestyle factors
and components of MetS, other than glucose, in order to correctly identify any independent
association between 25OHD and risk of T2DM. One other study [8] has also investigated the
association between 25OHD and T2DM and adjusted for three out of the four MetS compo-
nents. Thus our study appears to be one of the first to adjust for all MetS components. Impaired
fasting plasma glucose (FPG) and HbA1c levels are now recommended as key determinants of
early risk of T2DM [22]. While high FPG is an immediate indicator of poor glucose homeosta-
sis, HbA1c is a better indicator of longer term control of blood glucose, and recommended cut-
offs for both these biomarkers are used to diagnose T2DM [22]. The underlying hypothesis of
the present investigation was that increases in 25OHD would reduce the odds ratio of a high




The Victorian Health Monitor (VHM) survey was a state-wide cross-sectional population based
study [23] conducted in Victoria, Australia. Victoria lies in the south-east of Australia, and has a
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latitude of 37˚47’S and longitude of 144˚58’E. Data was collected between May 2009 and April
2010 including: physical information, dietary behaviour information and biomedical informa-
tion. The physical and biomedical information of participants were collected by trained staff at
four training sites. The VHM employed a stratified cluster sample selection method of Census
Collection Districts within eight Department of Health regions in Victoria. Data were collected
on 3,653 adults aged 18–75 years. From this sample, we excluded participants with: missing
HbA1c and FPG data (n = 31), those with HbA1c6.5% (n = 39) and FPG>7 mmol/L (n = 16)
as they were classified as having T2DM as per the American Diabetes Association (ADA) cut-offs
[22], those with T2DM (n = 140), those with type 1 diabetes (n = 9), and those on diabetic medi-
cations (n = 25). A total of 3,393 subjects were included in this analysis. Further details on physi-
cal, dietary, and biomedical data collection and analysis have been previously described [17, 23,
24].
Biomedical measurements
Participants attended a testing site after an overnight fast of at least 10 hours. Blood samples
were collected by venepuncture, and were subsequently transported to a central laboratory in
Melbourne, Australia. Bloods were analysed for: FPG, HbA1c, 25OHD, high density lipopro-
tein cholesterol (HDL-C), and triglycerides (TG). The components in the blood were mea-
sured as follows: FPG using the hexokinase method, HbA1c using immunosassay (Roche
Integra chemistry analyser), 25OHD concentration were measured based on the DiaSorin
Corporation Liaison1 25OHD total assay HDL-C using elimination/catalase method; and TG
using GPO Trinder reagent set with serum blank. The blood pressure (BP) of participants was
measured by survey staff using an automated BP monitor, which was calibrated regularly [23].
Physical measurements
The anthropometric measurements were made at the testing sites by trained staff, and
included height, weight and waist circumference. Height was measured without shoes using a
stadiometer. Weight was measured without shoes and light clothing, using a digital weighting
scale. Waist circumference was measured using a steel measuring tape. Body mass index
(BMI) was calculated from the weight and height measurements [23].
Dietary and physical activity measurements
Dietary information was collected by multiple-pass 24 h diet recall using computer assisted
telephone interviews. Dietary recall interviews were conducted by dietitians from the Depart-
ment of Nutrition and Dietetics at Monash University in Melbourne, Australia. The Food-
Works1 nutrition software (FoodWorks1 Interview) were used for conducting the dietary
recalls. Based on the three dietary recalls, the mean intake for each nutrient was calculated and
used in the analysis [23]. Further information on the assessment of dietary intake data can be
found in our previous publications [17, 23]. Physical activity information was collected via
interviews with the participant. The time spent in physical activity was calculated based on the
sum of the time spent walking or performing moderate activity plus double the time spent in
vigorous activity (to indicate its greater intensity) [23, 25].
FPG and HbA1c
Fasting plasma glucose and HbA1c were the two dependent variables. The ADA cut-offs were
used to identify those who were at a risk of T2DM based on FPG and HbA1c levels[22]. A
binary variable was used to categorize subjects as being at low or high risk for T2DM: FPG
Vitamin D status and risk of type 2 diabetes
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<5.6 mmo/L (low risk, normal), vs. 5.6–6.9 mmol/L (high risk), and HbA1c <5.7% (low risk,
normal) vs. 5.7–6.4% (high risk).
25OHD concentration
25OHD concentration was the primary independent variable. 25OHD concentration were cat-
egorized as tertiles: low 25OHD (median 33 nmol/L; range 10–44 nmol/l), medium 25OHD
(median 54 nmol/L; range 45–65 nmol/L) and high 25OHD (median 77 nmol/L; range 65–204
nmol/L).
Statistical analysis
Socio-demographic factors. In our analysis we considered a number of confounders,
based on our [26] and others experience in the area [12, 27]. We adjusted for the following
socio-demographic factors: age, gender, county of birth, Index of Relative Socio-economic
Disadvantage (IRSED), physical activity, smoking status, and season. Age were entered as con-
tinuous variables. Country of birth was categorized as those born in Australia or overseas. The
socio-economic indicator used was the IRSED, which is an index based on the social and eco-
nomic conditions of individuals within an area [28]. Subjects were categorized into IRSED
quartiles: quartile 1 (most disadvantaged), quartile 2 (disadvantaged), quartile 3 (less disadvan-
taged), and quartile 4 (least disadvantaged). Physical activity levels were classified into three
categories: sufficient activity (150 minutes/week), insufficient activity (1–149 minutes/week),
and inactive (0 minutes/week). There is a known seasonal variation to FPG and HbA1c, so we
had to adjust for season [29, 30]. Season of biomedical assessment refers to the season of the
year that the participant attended the testing site, and had their bloods collected for assessment
of 25OHD status. Season of biomedical assessment were grouped as summer, autumn, winter,
and spring. Smoking status were categorized into three categories: current smoker, ex-smoker,
and non-smoker.
Dietary factors. Based on previous research [31–33] dietary factors included in the analy-
ses were: dietary fiber, magnesium, alcohol, calcium, zinc, carbohydrate intake, energy intake
and under/over reporting of energy intake. Self-reported energy intake may result in the under
or over reporting of true energy intake (EI), and this may confound the estimation of any diet
and disease related outcomes [34]. We predicted basal metabolic rate (BMR) using the Henry/
Oxford equations based on a range of ages (18–30, 30–60, 60–70, and 70 and above years), gen-
der and body weight [35]. Rather than use the Goldberg cut-offs to identify under-reporters
and over-reporters [36], we calculated the ratio of energy intake to BMR (EI:BMR) and treated
it as a confounder. Dietary fiber, magnesium, alcohol, calcium, zinc, carbohydrate intake,
energy intake, and under/over reporting of energy intake were all entered as continuous
variables.
Biomedical factors. Biomedical factors included in the analyses were: MetS components
including waist circumference, high density lipoprotein (HDL) cholesterol, triglycerides (TG),
BP, as well as body mass index (BMI), and haemoglobin levels (HbA1c model only). Haemo-
globin levels were adjusted for in the HbA1c model only, as recent findings have indicated that
haemoglobin levels may increase HbA1c levels [37, 38]. BMI and haemoglobin levels were
entered as a continuous variable. Those with MetS tend to be at higher risk of developing
T2DM, thus we adjusted for MetS components in the HbA1c and FPG model [39]. MetS com-
ponents were each classified as binary variables, as defined by the joint interim statement [40].
Waist circumference were: normal waist circumference (<94cm for males or if Aboriginal or
Torres Strait Islander (ATSI), Asian or South American <90cm; <80cm for females), or ele-
vated waist circumference ( 94cm for males or if ATSI, Asian or South American90cm;
Vitamin D status and risk of type 2 diabetes
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80cm for females). HDL cholesterol were: normal HDL (1.0 mmol/L for males;1.3
mmol/L for females), or low HDL (<1,0 mmol/l for males;<1.3 mmol/L for females). TG
were: normal TG (<1.7 mmol/l), or hypertriglyceridaemia (1.7 mmol/l). BP were: normal
BP (<130/85 mmHg and no anti-hypertensive medications), or high BP (130/85 mmHG or
on anti-hypertensive medications) [40].
Statistical analysis. The statistical analysis was conducted in the following two stages:
Step 1: Descriptive statistics for HbA1c and FPG were obtained and normality was assessed
for variables of interest (natural logarithm transformation was applied if variable was skewed).
Differences between groups were then examined by Independent samples t test and χ2 test.
Step 2: Multiple logistic regression analyses were employed to obtain adjusted odds ratio
(AOR) and 95% CI for the associations between serum 25OHD and having higher HbA1c and
FPG, respectively. Three categories of variables were used in the regression models including:
socio-demographic variables (age, sex, country of birth, IRSED, physical activity, smoking sta-
tus, and season), dietary factors (dietary fiber, magnesium, alcohol, calcium, zinc, carbohydrate
intake, energy intake, and under/over reporting of energy intake) and biomedical variables
(MetS components: waist circumference (ethnic specific cut-offs), HDL cholesterol (normal/
low), TG (normal/high), BP (normal/high), BMI and haemoglobin levels for the HbA1c model
only). All these variables have a known association with FPG and HbA1c and have been previ-
ously reported in the literature.
The primary research variable of interest, serum 25OHD, was entered into the multiple
regression model as 1) a continuous variable (10 nmol/L increments) and also as 2) a categori-
cal variable based on 25OHD tertiles. For both continuous and categorical 25OHD, the multi-
ple regression model was initially adjusted for the socio-demographic variables in Model 1;
secondly both socio-demographic variables, dietary factors and haemoglobin levels (HbA1c
model only) in Model 2; and finally all socio-demographic, dietary factors and biomedical vari-
ables altogether in Model 3. The IBM SPSS Statistics for Windows, Version 21.0, was used for
the statistical analyses. The VHM survey employed the use of the multistage stratified cluster-
sampling procedure. In order to adjust for the unequal selection probability due to this sam-
pling method, complex samples analysis was used. Complex samples approach takes into
account the complex survey sampling and selection probability used in the VHM survey. Vari-
ables (strata variable, weighting variable and clustering variable) describing the survey design
in terms of stratification, clustering and multistage sampling were entered into the SPSS com-
plex samples approach for generating sampling weights in estimation and standard errors. A
two-tailed p value of less than 0.05 was accepted as statistical significance.
Results
An overview of socio-demographic, dietary and clinical characteristics of subjects based on
FPG and HbA1c levels are shown in Table 1 (please refer to S1 Table for the full socio-demo-
graphic, dietary and clinical characteristics of subjects). The prevalence of those with normal
FPG (<5.6 mmol/L) was 84% and for high FPG (5.6–6.9 mmol/L) was 16%. 61% of the popula-
tion had normal HbA1c (<5.6%), while 39% had high HbA1c (5.7–6.4%).
Association between serum 25OHD and FPG
When the serum 25OHD was entered as a continuous covariate to the multiple regression
model, for every increment in serum 25OHD of 10 nmol/L, the odds of having higher FPG
reduced by 9% (AOR 0.91, (0.86, 0.97); p = 0.002) after adjusting for socio-demographic vari-
ables, dietary factors, and biomedical variables in Model 3. For all models when serum
25OHD was entered as a categorical factor, compared with those people in the low 25OHD
Vitamin D status and risk of type 2 diabetes
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tertile, those with the high 25OHD tertile had a significantly reduced risk of higher FPG. More
specifically, after adjustment for both socio-demographic, dietary factors and BMI in Model 2
the odds of having higher FPG reduced by 40% for those in high 25OHD tertile (AOR 0.60,
(0.43, 0.83); p = 0.008) vs. low 25OHD tertile. After further adjustment for MetS components
Table 1. Socio-demographic and clinical characteristics of participants by FPG and HbA1c.
FPG (<5.6 mmol/L)
n = 2866 (84%)
FPG (5.6–6.9 mmol/L)
n = 527 (16%)
P value HbA1c (<5.7%)
n = 2068 (61%)
HbA1c (5.7–6.4%)
n = 1325 (39%)
P value
Mean (SE) or N (SE) % Mean (SE) or N (SE) % Mean (SE) or N (SE) % Mean (SE) or N (SE) %
Age (y) 42 (0.8) 52 (1.4) <0.001 40 (0.9) 52 (0.9) <0.001
BMI (kg/m2) 26.6 (0.2) 29.2 (0.4) <0.001 26.2 (0.2) 28.8 (0.2) <0.001
Gender <0.001 0.494
Males 1285 (1.5) 81% 299 (1.5) 19% 1112 (2.5) 70% 472 (2.5) 30%
Females 1663 (1.0) 91% 162 (1.0) 9% 1257 (2.4) 69% 577 (2.4) 31%
Country of birth 0.031 <0.001
Born in Australia 2264 (0.7) 88% 320 (0.7) 12% 1868 (2.1) 72% 716 (2.1) 28%
Born overseas 674 (1.9) 83% 134 (1.9) 17% 505 (3.6) 62% 303 (3.6) 38%
IRSED 0.020 0.216
Most disadvantaged 705 (1.7) 83% 142 (1.7) 17% 545 (5.1) 64% 302 (5.1) 36%
Disadvantaged 732 (1.0) 87% 108 (1.0) 13% 570 (3.8) 68% 270 (3.8) 32%
Less disadvantaged 765 (1.3) 89% 98 (1.3) 11% 639 (4.1) 74% 224 (4.1) 26%
Least disadvantaged 737 (1.2) 87% 106 (1.2) 13% 631 (3.3) 75% 212 (3.3) 25%
Smoking status <0.001 0.002
Current smoker 441 (2.2) 84% 86 (2.2) 16% 366 (3.7) 69% 161 (3.7) 31%
Ex-smoker 733 (2.0) 80% 179 (2.0) 20% 575 (3.2) 63% 337 (3.2) 37%
Non-smoker 1756 (0.9) 90% 195 (0.9) 10% 1418 (2.1) 73% 533 (2.1) 27%
25OHD concentration
Serum 25OHD (nmol/L) 56.7 (2.0) 52.1 (2.5) 0.081 57.2 (2.2) 53.6 (1.9) 0.208
25OHD tertiles 0.045 0.135
Low 25OHD (33 nmol/L) 933 (1.5) 84% 180 (1.5) 16% 745 (2.9) 67% 359 (2.9) 33%
Medium 25OHD (54 nmol/
L)
992 (1.3) 85% 168 (1.3) 15% 798 (3.5) 69% 32 (3.5) 31%
High 25OHD (77 nmol/L) 1013 (1.5) 90% 116 (1.5) 10% 829 (2.4) 73% 300 (2.4) 27%
Dietary variable
Energy (kJ/d) 9687.4 (116.5) 9784.9 (164.9) 0.653 9904.4 (147.8) 9236.4 (145.6) <0.001
Biomedical factors
Waist circumference (cm) 88.0 (0.7) 96.9 (1.1) <0.001 86.9 (0.7) 94.7 (0.9) <0.001
Triglycerides (mmol/L) 1.2 (0.03) 1.5 (0.04) <0.001 1.1 (0.03) 1.5 (0.04) <0.001
HDL (mmol/L) 1.5 (0.02) 1.4 (0.03) <0.001 1.5 (0.02) 1.4 (0.02) <0.001
Systolic blood pressure
(mmHg)
123 (0.6) 133 (1.1) <0.001 123 (0.7) 128 (0.6) <0.001
Diastolic blood pressure
(mmHg)
73 (0.5) 77 (0.7) <0.001 72 (0.5) 76 (0.5) <0.001
Haemoglobin levels (g/L) 142.9 (0.4) 148.2 (1.1) <0.001 144.2 (0.4) 142.4 (0.6) <0.001
Data are presented as mean estimate (weighted) (%) for categorical variables, and mean estimate (weighted) and (SE) for normal continuous variables.
Difference in the continuous and categorical variables between groups were assessed by independent samples t-test (natural logarithm transformation was
used if the variable was not normal) and Chi-square test (association between FPG or HbA1c and categorical variables, with an emphasis on which
category were more likely to have high FPG, or high HbA1c), respectively.
Legend: d, day; SE, standard error; min, minutes; wk, week.
https://doi.org/10.1371/journal.pone.0178825.t001
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in Model 3, the AOR appeared relatively stable with a 39% reduced odds of higher FPG in the
high 25OHD vs. low 25OHD tertile (AOR 0.61, (0.44, 0.84); p = 0.011) (Table 2).
Association between serum 25OHD and HbA1c
In Model 3 after adjustment for socio-demographic, dietary, and biomedical variables every 10
nmol/L increment in 25OHD also significantly reduced the odds of higher HbA1c by 6%
(AOR 0.94, (0.90, 0.98); p = 0.009). In Model 2, after adjustment for socio-demographic vari-
ables, dietary factors, BMI and haemoglobin levels, there was a significantly reduced odds of
having higher HbA1c by 33% in those with high vs. low 25OHD tertile. After further adjust-
ment for MetS components in Model 3, a 26% reduced odds of higher HbA1c (AOR 0.74,
(0.58, 0.93); p = 0.041) were found in the high 25OHD tertile group, compared to the low
25OHD tertile group (Table 3).
Discussion
The results from this population based study of adults from Victoria, Australia indicate that
higher 25OHD levels were significantly related to a reduced risk of higher FPG and HbA1c lev-
els. This significant inverse association persisted after the adjustment for a number of socio-
demographic, dietary, and biomedical variables and MetS components. We found that those
in the high 25OHD tertile had a 39% reduced risk of higher FPG and 26% reduced risk of
higher HbA1c, when compared to the low 25OHD tertile. This was independent of MetS com-
ponents, and haemoglobin levels in the HbA1c model, which have been found to confound
the association between 25OHD and T2DM. Two recent meta-analyses [41–42] found no sig-
nificant effect of vitamin D supplementation on IR [41], FPG [41, 42] or HbA1c [42]. Though,
another found a beneficial effect of vitamin D supplementation on FPG and HbA1c, despite
no effect on IR [43]. Our recent review summarised that although there were inverse associa-
tions between 25OHD and IR, the systematic reviews and meta-analysis in that review did not
favour a casual role [44]. The present findings are in line with previous observational studies
that found an inverse association between 25OHD status and high FPG levels [20, 45] and
Table 2. The association of serum 25OHD and FPG: Crude and adjusted odds ratio and their 95% CI based on logistic regression.
Model 1 Model 2 Model 3
Crude OR 95% CI AOR 95% CI AOR 95% CI
25OHD continuous (10 nmol/L) 0.93 0.87, 1.01 0.91 0.86, 0.97 0.91 0.86, 0.97
P value 0.054 0.003 0.002
Model 1 Model 2 Model 3
25OHD tertiles Crude OR 95% CI AOR 95% CI AOR 95% CI
Low 25OHD (33 nmol/L) † 1.0 1.0 1.0
Medium 25OHD (54 nmol/L) † 0.89 0.60, 1.31 0.87 0.57, 1.32 0.87 0.59, 1.29
High 25OHD (77 nmol/L) † 0.66* 0.46, 0.94 0.60* 0.43, 0.83 0.61* 0.44, 0.84
P value for trend 0.076 0.008 0.011
Model 1: age, sex, country of birth, IRSED, physical activity, smoking status, season, BMI.
Model 2: Model 1 plus dietary fiber, magnesium, alcohol, calcium, zinc, carbohydrate intake, energy intake, under/over reporting of energy intake.
Model 3: Model 2 plus waist circumference, HDL cholesterol, TG, BP; all as categorical variables based on MetS cut-offs.
Legend: Crude OR, crude odds ratio; AOR, adjusted odds ratio; 1.0, lowest 25OHD served as the reference group.
Footnotes
*, significant in comparison to reference group at 5% significance level
†, median of the tertile group.
https://doi.org/10.1371/journal.pone.0178825.t002
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high HbA1c levels [46–51]. However, these studies adjusted for fewer variables, with smaller
sample sizes than our study and were not population based [45, 49–51]. The differences in
findings between both interventional and observational based studies indicates a need for
good quality randomized controlled trials.
A number of inter-related factors contribute to the pathogenesis of T2DM, including the
presence of MetS components. One prospective study found that those with IR and high FPG
(5.6–6.9 mmol/L) had double the risk of worsened cardio-metabolic profile after nine years
[52]. Obesity, dyslipidemia and hypertension are MetS components which are often found in
those with pre-diabetes [53]. We adjusted for these variables in our analysis and found that the
association between 25OHD and risk of T2DM still existed, irrespective of MetS. Other studies
investigating 25OHD and risk of T2DM have adjusted for either none [47–49], or one MetS
components [46, 54, 55], with one study accounting for all of the MetS components [8].
Potential mechanisms
The beneficial effect of 25OHD in reducing risk of T2DM is likely due to its effect on insulin
action. The expression of the vitamin D receptor (VDR) in pancreatic beta cells indicates the
importance of vitamin D in beta cell function [56, 57] and insulin secretion [5]. During times
of vitamin D deficiency, beta cell function is blunted and insulin secretion is diminished [58].
Vitamin D may also indirectly influence insulin action via a calcium mediated effect. Vitamin
D tightly regulates calcium homeostasis, whereby intracellular calcium levels are required to
ensure effective action of insulin within different tissues [56]. Vitamin D is also involved in the
regulation of the renin angiotensin system [59], endothelial vasodilation and lipid levels [60]
which are mechanisms relating to the MetS components. T2DM and MetS are inter-twined,
wherein IR appears to be a key player in the development of both conditions [61, 62]. Though
there are commonalties in the mechanisms underlying both conditions, our study found that
even on adjustment for MetS components, the association between the high 25OHD tertile
and lower odds of higher FPG and HbA1c levels persisted. This may potentially suggest that
vitamin D has a beneficial role in T2DM, independent of MetS. However, the cross-sectional
nature of this study does not provide further insight into this observation.
Table 3. The association of serum 25OHD and HbA1c: Crude and adjusted odds ratio and their 95% CI based on logistic regression.
Model 1 Model 2 Model 3
Crude OR 95% CI AOR 95% CI AOR 95% CI
25OHD continuous (10 nmol/L) 0.93 0.88, 0.97 0.93 0.88, 0.97 0.94 0.90, 0.98
P value 0.002 0.002 0.009
Model 1 Model 2 Model 3
25OHD tertiles Crude OR 95% CI AOR 95% CI AOR 95% CI
Low 25OHD (33 nmol/L) † 1.0 1.0 1.0
Medium 25OHD (54 nmol/L) † 0.78 0.56, 1.09 0.79 0.56, 1.11 0.83 0.58, 1.17
High 25OHD (77 nmol/L) † 0.68* 0.54, 0.86 0.67* 0.53, 0.85 0.74* 0.58, 0.93
P value for trend 0.007 0.005 0.041
Model 1: age, sex, country of birth, IRSED, physical activity, smoking status, season, BMI.
Model 2: dietary fiber, magnesium, alcohol, calcium, zinc, carbohydrate intake, energy intake, under/over reporting of energy intake, haemoglobin levels.
Model 3: Model 2 plus waist circumference, HDL cholesterol, TG, BP; all as categorical variables based on MetS cut-offs.
Legend: Crude OR, crude odds ratio; AOR, adjusted odds ratio; 1.0, lowest 25OHD served as the reference group.
Footnotes
*, significant in comparison to reference group at 5% significance level
†, median for the tertile group.
https://doi.org/10.1371/journal.pone.0178825.t003
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Low grade chronic inflammation is a hallmark of many chronic diseases and may precede
T2DM [63] possibly via initiation of IR [64]. Vitamin D has a role in immunity, and cellular
studies show consistent reduction of inflammatory markers following cholecalciferol supple-
mentation [65]. Adequate circulating 25OHD levels are required to obtain optimal anti-
inflammatory responses in the body [66], especially in those tissues like immune cells, where
the enzymes for conversion of 25OHD to 1,25OH2D are present. However, the optimum
25OHD levels for modulating inflammation responses are yet to be determined [67]. There is
plausible but not confirmatory evidence to suggest the value is around 75–80 nmol/L [68, 69];
a point where maximum suppression of parathyroid hormone is also expected [70]. In sup-
port, a recent review [71], and emerging randomized controlled trials [72, 73] found beneficial
effects of vitamin D supplementation on IR and fat loss in those individuals who reached this
value over the period of the trial [72, 73]. In the present study those in the highest 25OHD ter-
tile had a median of 77 nmol/L, where reduced risk of higher FPG and HbA1c was observed.
Limitations
The cross-sectional design does not afford causality of association, though we have controlled
for several known confounders. The VHM did not collect information on supplement use, so
we cannot separate the potential effects of vitamin D supplement and increased sun exposure
on the higher 25OHD levels. Family history of T2DM may increase the risk of development of
the disease [74], but unfortunately such information was not collected as part of the survey
thus is a potential confounder. Approximately >75% of our sample were born in Australia, so
potential effects of country of birth/ethnicity could not be determined.
Studies have indicated that 25OHD may vary due to the genetic variation of three polymor-
phisms in the vitamin D genes, including the vitamin D binding protein, VDR and the 25OHD
activating enzyme [75, 76]. The concentration of the vitamin D binding protein may vary
between individuals [77, 78] as well as fluctuations in its binding affinity [79]. There may also
be a genetic association between VDR polymorphisms and T2DM. Recent evidence has found
that the polymorphism of certain VDRs may increase susceptibility to T2DM [80] and certain
MetS components [81]. Lastly, the conversion of 25OHD to its active form requires CYP27B1,
an enzyme that may be affected by genetic variation [82]. These genetic variants were not stud-
ied as part of the VHM survey but certainly provide avenues for novel insights into the associa-
tions described here.
Strengths
This study used a representative sample of adult Australians from one state of the country. We
adjusted for a wide range of socio-demographic, biomedical and dietary factors. Our study
appears to be one of the few [8] which has accounted for all MetS components when investigat-
ing associations between 25OHD and T2DM. We also adjusted for the possible misreporting
of energy intakes [35]. That being said 24 h recalls in this study were obtained from a five-pass
method which is considered the gold standard for dietary information. We also adjusted the
HbA1c analysis for haemoglobin concentrations, since concomitant anaemia may be associ-
ated with inaccurate HbA1c levels [37, 38]. Other studies in the area have not adjusted for this
factor [8, 46–49, 54, 55].
Conclusions
Higher 25OHD status was associated with lower prevalent FPG as well as lower HbA1c con-
centrations after accounting for socio-demographic, lifestyle variables and MetS components.
Such outcomes could suggest a direct role for the vitamin in the prevention of T2DM.
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